Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Macrophage Phenotype–Dependent Protein Corona Formation Governs Ligand Accessibility and Immune Clearance of Biomimetic Nanoparticles
Researchers coated magnetic silica nanoparticles with membranes from naïve (M0), classically activated (M1) and alternatively activated (M2) macrophages to study phenotype‑dependent protein corona formation. Proteomic analysis showed M0‑derived membranes adsorbed the fewest opsonins (C3, IgG, IgM) and triggered the lowest complement activation. In vivo, M0‑coated particles exhibited reduced hepatic clearance and significantly longer blood circulation than M1 or M2 counterparts. The study highlights source‑cell phenotype as a critical factor shaping corona composition and nanocarrier fate.
Senseonics Launches Automated Insulin Dosing System with 1-Year CGM
Senseonics and Sequel Med Tech have launched an automated insulin‑delivery system that pairs the year‑long Eversense 365 implantable CGM with Sequel’s twiist pump. The integration, delayed to Q4 2025, marks the first AID solution using a one‑year sensor, contrasting with competitors’ 15‑day...
Continuing Our Efforts to Address Violence
The American Hospital Association (AHA) is intensifying its fight against violence in health‑care settings by releasing a joint guide with the FBI on behavioral threat assessment and management (BTAM). The guide provides evidence‑based strategies, training recommendations, and case studies from...
AI in Cardiovascular Imaging and Interventions: Boon or Bane?
At the 2026 EAPCI Summit, experts highlighted AI’s expanding role in cardiovascular interventions, from mortality risk modeling to intravascular imaging analysis. A University of Galway study identified gamma‑glutamyl transferase as a strong 10‑year mortality predictor in the SYNTAX cohort, validated...
From Junk Science (Largely Non-Political) to Junk Medical Treatments (Mostly Associated with the Far-Right): A Financial Connection
Paul Krugman highlights a growing financial link between the multi‑billion‑dollar wellness industry and right‑wing extremist movements. He notes that U.S. spending on wellness reaches roughly $500 billion annually, with nutritional supplements alone accounting for about $70 billion, while regulators like the FDA...
A Quercetin Nanocarrier‐Loaded Dual Network Injectable Hydrogel for Mesenchymal Stem Cells (MSCs) Delivery Targeting Osteoarthritis
Researchers have created an injectable dual‑network hydrogel composed of gelatin methacrylate and κ‑carrageenan that embeds quercetin‑loaded PLGA nanoparticles for mesenchymal stem cell (MSC) delivery in osteoarthritis (OA). The antioxidant hydrogel scavenges reactive oxygen species, reprograms M1 macrophages to an anti‑inflammatory...
Advanced Approaches to Pediatric Fluid and Electrolyte Therapy: What Pharmacists Need to Know
The article outlines modern pediatric fluid and electrolyte therapy, emphasizing isotonic maintenance IV solutions to curb hyponatremia and detailing the Holliday‑Segar and BSA‑based calculation methods. It differentiates oral rehydration for mild‑to‑moderate dehydration from phased isotonic bolus and deficit‑plus‑maintenance IV regimens...
STAT+: Pharmalittle: We’re Reading About an FDA Official’s Speech, a Grail Cancer Blood Test, and Much More
FDA drug‑center head Tracy Beth Høeg used her first staff address to flag two priority areas: the safety of antidepressants taken during pregnancy and the use of monoclonal antibodies that protect infants from RSV. She also signaled a continued interest...
The Pulse of Pharma Change in 2026
In a February 20, 2026 Pharm Exec Podcast, ZS CEO Pratap Khedkar, PhD, outlined three converging trends reshaping pharma: heightened AI integration, evolving ecosystem partnerships, and sweeping US‑driven policy reforms. Drawing on his nine‑year tenure leading ZS’s global pharmaceuticals practice and its advanced data‑science...
Ready to Grow Your Surgery Center Without Losing Your Sanity
Surgery centers are expanding rapidly, but growth brings regulatory, staffing, and technology challenges that can overwhelm internal teams. Without a structured plan, new service lines often trigger credentialing, supply chain, and workflow gaps, leading to delays and cost overruns. Ambulatory...
To Streamline Workflows, Listen to Clinicians
Chief Clinical Officer Dr. Michael Zappa of Cape Fear Valley Health, also a physician advisor at Juno Health, urges healthcare leaders to directly ask clinicians which administrative duties pull them away from patient care. He recommends mapping these tasks and...
Exercise‑induced Liver Enzyme GPLD1 Restores Memory, Boosts Vascular Health
Liver enzyme GPLD1 produced during exercise reverses aging- and Alzheimer’s-related memory loss by improving vascular health https://www.cell.com/cell/fulltext/S0092-8674%2826%2900111-X
FDA Starts Review of Regeneron's Drug for Rare Disease FOP
The FDA has placed Regeneron's anti‑activin A antibody garetosmab under priority review, with a decision expected by August. Phase 3 OPTIMA data showed a 94% reduction in new heterotopic ossification lesions at the lower dose and a 90% reduction at the higher...
Evolving Frontline Treatment Strategies in Diffuse Large B-Cell Lymphoma
Frontline treatment of diffuse large B‑cell lymphoma (DLBCL) is shifting from traditional R‑CHOP toward targeted and bispecific antibody‑based regimens. The POLARIX phase‑3 trial demonstrated that Pola‑R‑CHP improves progression‑free survival, particularly in activated‑B‑cell (ABC) disease and older patients. Early phase studies...
Nanozyme Aptasensor: A Breakthrough in S. Aureus Diagnostics
Researchers have unveiled a nanozyme‑aptamer colorimetric array that classifies Staphylococcus aureus strains with 100% accuracy, including methicillin‑resistant variants. The platform couples gold‑nanoparticle nanozymes with four strain‑specific aptamers, producing distinct color fingerprints that are decoded by hierarchical clustering and linear discriminant...
Allonic’s 3D Tissue‑Braided Robots Mimic Human Connective Tissue
The technology is undeniably impressive — but it carries a distinct 'Westworld' vibe. Anybody else feeling it? Allonic, a robotics startup based in Hungary, is developing humanoid robot bodies using a proprietary 3D "Tissue Braiding" system. The process weaves high-strength fibers, elastic...
Teens with Dogs Show Better Mental Health, Fewer Issues
Is it ok to let your kids kiss the dog? A new study found that teenagers who live with dogs show better mental health and fewer social difficulties. In a group of 343 teens, dog owners scored better across five behavioral measures:...
CHS Could Slow Pace of Divestitures as It Makes Progress Paying Debt
Community Health Systems (CHS) announced it will decelerate its aggressive divestiture program as it focuses on strengthening core markets. The for‑profit hospital chain has cut its debt leverage to 6.6× in 2025, down from 7.4× the year before, and boosted...
B.C. Snooping Scandal Puts Workplace Privacy – and Employer Liability – Under Microscope
A British Columbia privacy commissioner report revealed 36 healthcare workers accessed patient records in 71 separate incidents, highlighting a broader issue of employee snooping. Privacy lawyer Lyndsay Wasser says such unauthorized access is common across sectors, not limited to high‑profile...
New 2027 ACA Draft Rules Are Out. 8 Predictions About the Impact
The Centers for Medicare & Medicaid Services released draft ACA rules for 2027 that could make individual major‑medical coverage cheaper and more attractive. Key changes include broader availability of catastrophic plans, higher annual out‑of‑pocket caps, and the option for monthly...
No One-Trick Pony in Oncology, Merck’s Cancer Footprint Is Expanding
Merck is expanding beyond its flagship Keytruda by investing in diverse oncology platforms. In 2024 it spent $700 million on a bispecific candidate from Curon and $680 million to acquire Harpoon Therapeutics, bolstering its T‑cell engager portfolio. The company is also advancing...
FDA Approves Acalabrutinib with Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The FDA approved a fixed‑dose combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The decision is based on the AMPLIFY trial, which showed a 35% reduction in progression‑free survival risk compared...
The US FDA Accepts Roche’s Giredestrant NDA for ESR1-Mutated, ER-Positive Advanced Breast Cancer
The U.S. FDA has accepted Roche’s new drug application for giredestrant combined with everolimus to treat ER‑positive, HER2‑negative, ESR1‑mutated advanced breast cancer. Phase III evERA data show a 44% reduction in disease progression or death overall and a 62% reduction in...
UK Firm Steps in to Ease Medicine Supply Crisis in NHS
A shortage of bone cement from German supplier Heraeus Medical threatens NHS orthopaedic surgeries, potentially lasting two months. NHS England has asked trusts to prioritise emergency joint replacements, leaving elective patients at risk. UK‑based Biocomposites accelerated the launch of its...
Novartis to Divest India Unit to Private Equity-Led Consortium for $159M
Novartis announced the sale of its majority stake in its Indian generics and prescription business to a private‑equity‑led consortium for $159 million. The transaction transfers control of a portfolio that includes both off‑patent generics and branded medicines to the buyers. The...
Why “Eat Less, Move More” Fails for Midlife Weight Loss
Midlife women often follow the classic "eat less, move more" mantra yet see stagnant scales because perimenopause and menopause trigger profound physiological shifts. Hormonal fluctuations raise insulin and cortisol, blunt glucose flexibility, and promote fat oxidation over muscle use. Simultaneously,...
Stratasys Introduces 3D-Printed Dental Training Preset
Stratasys unveiled a new dental anatomical model preset that leverages its multi‑material 3D printing platform to produce highly detailed, biomechanically accurate replicas for dental education and device training. The preset standardizes material ratios and printing parameters, enabling on‑demand, repeatable models...
Levetiracetam Reduces Amyloid-Β Production in the Brain
Researchers report that the FDA‑approved antiepileptic levetiracetam reduces amyloid‑β42 production in mouse models of Alzheimer’s disease. The drug redirects amyloid precursor protein processing toward the non‑amyloidogenic pathway by modifying synaptic vesicle cycling and increasing surface APP expression. Mass‑spectrometry and electrophysiology...
Nobody Gets Sued but the Doctor: The Legal Vacuum at the Center of the AI Physician Revolution
The episode examines the legal vacuum surrounding AI‑assisted clinical decision‑making, highlighting that while the FDA has cleared over 1,300 AI medical devices, adoption remains low and physicians bear virtually all malpractice liability. Data shows a rapid rise in AI use...
Kontakt.io Unveils Next-Generation AI Solutions to Re-ViVE Care Operations and Transform Healthcare Delivery
Kontakt.io announced a suite of AI‑driven agents at ViVE 2026, combining real‑time location services (RTLS) with electronic health record data to create a digital twin of hospital operations. The portfolio—Patient Journey Analytics, Access Agent, Patient Flow Agent, and Supply Chain...
Pontiro Secures £357,500 to Expand Healthcare AI Infrastructure
Pontiro, a health‑tech firm that streamlines medical‑image data for AI, secured £357,500 in a round led by SFC Capital with participation from Plug and Play Ventures and the British Business Bank. The company’s platform has already processed more than two...
Pharma Pulse: J&J’s $1B Cell Therapy Hub and Hims & Hers’ Global Expansion
Johnson & Johnson announced a $1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Montgomery County, Pennsylvania, slated to support 500 skilled jobs. The hub is a key element of J&J’s $55 billion U.S. manufacturing, R&D, and technology strategy. Meanwhile,...
NKTR’s Alopecia Areata Play: Market Misprices Massive Upside
Ok, so I have finally gotten around to writing out my updated thoughts/thesis on $NKTR. Link in this post. I'm about as bullish on the stock now as I've ever been. The document is very long (sorry, but it's free...give me...
Screening Cuts Advanced Colon Cancer, Boosts Early Detection
Screening works for colon cancer. Largest trial ever done. Today @NatureMedicine A randomized trial of colon cancer screening by colonoscopy or occult blood (FIT) vs control in nearly 280,000 participants showed signficantly more early diagnosis (stage I-II) and less stage...
Ex-Novartis CMO John Tsai Joins Daiichi Sankyo
Daiichi Sankyo appointed former Novartis chief medical officer John Tsai as its new CMO, succeeding Ken Takeshita after a five‑year tenure. Tsai brings a record of launching 160 projects and 15 regulatory approvals, including Zolgensma and Pluvicto, and recent experience leading biotech...
NexEos Bio Receives US FDA IND Clearance to Advance NTX-1024 Into P-II/III Study for Vernal Keratoconjunctivitis
U.S. FDA has granted IND clearance for NexEos Bio’s ophthalmic solution NTX-1024, allowing the company to commence a combined Phase II/III clinical trial in vernal keratoconjunctivitis (VKC). The upcoming study will assess safety and efficacy after an open‑label investigator‑initiated trial...
Boehringer Ingelheim and NIPER Sign MoU on Pharmaceutical Research
Boehringer Ingelheim India has signed a memorandum of understanding with the National Institute of Pharmaceutical Education and Research (NIPER) in Raebareli to deepen collaboration on pharmaceutical technologies and novel drug delivery systems. The agreement grants NIPER access to Boehringer’s opnMe...
AZN's Calquence + Venetoclax Approved for CLL Treatment
#AZN Calquence combined with Venetoclax approved in US for treating Adults with Chronic Lymphocytic Leukaemia in a particular form.
How Medical Device Manufacturers Can Overcome Recruitment Gaps and Accelerate Innovation Hiring with Rapid Prototyping
Medical device makers face a perfect storm of innovation pressure and a severe talent shortage, causing development cycles to stretch 18‑24 months. Rapid prototyping technologies can compress these cycles by up to 40%, enabling faster design iteration and ISO 13485‑compliant...
En Carta Diagnostics Receives FDA Breakthrough Device Designation for EC Pocket Lyme Test
En Carta Diagnostics announced that its EC Pocket Lyme test has received FDA Breakthrough Device Designation, accelerating its path to U.S. market entry. The point‑of‑need molecular assay detects Borrelia DNA directly from skin interstitial fluid using a microneedle sampler, delivering...
Nurses Aren’t Burned Out, They’re Being Burned by the System
Recent data shows 53% of nurses consider leaving monthly, indicating systemic burnout. The national turnover rate of 16.4% costs about $61,110 per replacement, harming patient care and morale. HR leaders must address root causes—understaffing, erratic schedules, limited autonomy—through workforce planning,...
AngioDynamics Expands European Indications for NanoKnife System
AngioDynamics announced that its NanoKnife system now holds European CE‑mark indications for soft‑tissue ablation of liver, kidney, prostate and pancreas tumours, including intermediate‑risk prostate cancer. The device uses irreversible electroporation (IRE), a non‑thermal technology that destroys cancer cells while sparing...
Serina Therapeutics Enrols First Patient for SER-252 Trial
Serina Therapeutics has enrolled the first patient in its Phase Ib registrational trial of SER‑252 for advanced Parkinson’s disease. The study, conducted with Parkinson’s Australia and Neuroscience Trials Australia, will assess safety, pharmacokinetics, tolerability and early efficacy, with dosing slated to...
Syngene and VivaMed Collaborate on Therapeutic Programmes
Syngene International has entered a strategic collaboration with VivaMed BioPharma to advance AI‑derived drug repurposing programmes. The partnership combines Syngene’s pre‑clinical development capabilities with VivaMed’s AI‑generated therapeutic hypotheses, creating a pathway from computational hits to translational validation. Together they will...
Application Spotlight: AI-Designed Patient-Specific Spinal Implants Set for First In-Human Procedures in 2026
Nivalon, founded by Todd Hodrinsky and Marcel Janse, is preparing to launch its AI‑designed, patient‑specific spinal implant system, EvoFlex, in first‑in‑human trials slated for 2026. The implants are generated through machine‑learning algorithms that model each patient’s vertebral geometry, aiming to...
Accelerating Rare Disease Cures with ASOs, Gene Editing, and AI
Professor Matthew Wood, Oxford’s leading neuroscientist, heads the Oxford‑Harrington Rare Disease Centre, a partnership designed to fast‑track therapies for rare neuromuscular and genetic disorders. He outlines a vision to make antisense oligonucleotides (ASOs) and gene‑editing tools more modular, scalable, and...
4.2m Eye Health Research Hub Set for North East
A £4.2 million Northern Ophthalmic Research and Innovation Institute (NORI) is being established in North East England to turn routine eye scans into early‑warning tools for serious illnesses. The hub, hosted by the University of Sunderland, will link eye images with...
AM Best’s Briefing – Health: Medicare Advantage – Challenges and Opportunities
The episode provides an overview of the current Medicare Advantage (MA) landscape, highlighting regulatory changes, enrollment trends, and financial pressures facing insurers. It examines challenges such as rising cost of care, tighter network requirements, and the impact of the Medicare...
Leica Launches CM1950 Cryostat with DualEcoTec Cooling System
Leica Biosystems, a Danaher subsidiary, unveiled the Leica CM1950 cryostat equipped with DualEcoTec cooling. The device cools specimens up to three times faster and chambers up to twice as fast, slashing setup and case times. It employs a near‑zero global...
Boehringer Ingelheim Secures US FDA’s EUA for NexGard and NexGard COMBO to Treat NWS
Boehringer Ingelheim received an Emergency Use Authorization (EUA) from the U.S. FDA for its NexGard chewable tablets to treat New World screwworm (NWS) infestations in dogs and puppies, and for NexGard COMBO topical solution to treat NWS in cats and...